These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 14555538

  • 1. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH.
    Clin Cancer Res; 2003 Oct 01; 9(12):4619-26. PubMed ID: 14555538
    [Abstract] [Full Text] [Related]

  • 2. Antitumor interaction of short-course endostatin and ionizing radiation.
    Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR.
    Cancer J; 2000 Oct 01; 6(5):287-93. PubMed ID: 11079167
    [Abstract] [Full Text] [Related]

  • 3. [Studies on antitumor activity of rhEndostatin].
    Li HY, Li Y, Liu ZH, Wu HJ, Chen FH, Chen XG.
    Yao Xue Xue Bao; 2002 Oct 01; 37(10):763-6. PubMed ID: 12567857
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
    Zhu LP, Xing J, Wang QX, Kou L, Li C, Hu B, Wu ZW, Wang JJ, Xu GX.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):23-7. PubMed ID: 19615993
    [Abstract] [Full Text] [Related]

  • 5. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases.
    Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL.
    Proc Natl Acad Sci U S A; 2000 Apr 25; 97(9):4802-7. PubMed ID: 10758166
    [Abstract] [Full Text] [Related]

  • 6. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma.
    Lingen MW, Polverini PJ, Bouck NP.
    Cancer Res; 1998 Dec 01; 58(23):5551-8. PubMed ID: 9850093
    [Abstract] [Full Text] [Related]

  • 7. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
    Guo Y, Mazar AP, Lebrun JJ, Rabbani SA.
    Cancer Res; 2002 Aug 15; 62(16):4678-84. PubMed ID: 12183425
    [Abstract] [Full Text] [Related]

  • 8. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH.
    Ann Surg Oncol; 2009 May 15; 16(5):1403-11. PubMed ID: 19263173
    [Abstract] [Full Text] [Related]

  • 9. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
    Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y, Johnson F, Engleman EG, Nolan GP.
    Mol Ther; 2001 Feb 15; 3(2):186-96. PubMed ID: 11237675
    [Abstract] [Full Text] [Related]

  • 10. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.
    Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038
    [Abstract] [Full Text] [Related]

  • 11. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.
    Anticancer Res; 2004 Jan 01; 24(3a):1759-63. PubMed ID: 15274352
    [Abstract] [Full Text] [Related]

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 13. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.
    Cancer Res; 2002 Dec 15; 62(24):7247-53. PubMed ID: 12499266
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
    Gautam SC, Chikkala NF, Ganapathi R, Hamilton TA.
    Cancer Res; 1991 Nov 15; 51(22):6133-7. PubMed ID: 1682042
    [Abstract] [Full Text] [Related]

  • 15. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 16. [Inhibition of tumor growth and metastasis via local administration of recombinant human endostatin adenovirus].
    Wu Y, Yang L, Zhao X, Su JM, Hu B, Liu JY, Niu T, Luo Y, Li Q, Wei YQ.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Dec 15; 21(6):557-61. PubMed ID: 15583981
    [Abstract] [Full Text] [Related]

  • 17. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo.
    Xu YF, Zhu LP, Hu B, Rong ZG, Zhu HW, Xu JM, Wu ZW, Wang JJ, Xu GX.
    Eur J Pharmacol; 2007 Jun 14; 564(1-3):1-6. PubMed ID: 17346697
    [Abstract] [Full Text] [Related]

  • 18. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 19. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M.
    Clin Cancer Res; 2003 Nov 01; 9(14):5358-69. PubMed ID: 14614021
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.